MeSH

New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Year introduced: /diagnosis was NEOPLASM DIAGNOSIS 1964-1965

Newly arising secondary tumors so small they are difficult to detect by physical examination or routine imaging techniques.

Year introduced: 2012

Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.

Year introduced: 2012

Genes whose abnormal expression, or MUTATION are associated with the development, growth, or progression of NEOPLASMS.

Year introduced: 2006

Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.

Year introduced: 1996

Remnant of a tumor or cancer after primary, potentially curative therapy.

Year introduced: 1995

RNA present in neoplastic tissue.

Experimental transplantation of neoplasms in laboratory animals for research purposes.

Year introduced: 1967(1964)

Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.

Year introduced: 1978

The local implantation of tumor cells by contamination of instruments and surgical equipment during and after surgical resection, resulting in local growth of the cells and tumor formation.

Year introduced: 1970(1966)

Disappearance of a neoplasm or neoplastic state without the intervention of therapy.

Year introduced: 1964

The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.

Year introduced: 1966(1964)

Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.

The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.

Ability of neoplasms to infiltrate and actively destroy surrounding tissue.

Year introduced: 1977

DNA present in neoplastic tissue.

Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.

Year introduced: 1973

Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.

Year introduced: 1973

Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.

Year introduced: 1978

Benign and malignant intra-axial tumors of the MESENCEPHALON; PONS; or MEDULLA OBLONGATA of the BRAIN STEM. Primary and metastatic neoplasms may occur in this location. Clinical features include ATAXIA, cranial neuropathies (see CRANIAL NERVE DISEASES), NAUSEA, hemiparesis (see HEMIPLEGIA), and quadriparesis. Primary brain stem neoplasms are more frequent in children. Histologic subtypes include GLIOMA; HEMANGIOBLASTOMA; GANGLIOGLIOMA; and EPENDYMOMA.

Year introduced: 2000